摘要:
The present embodiments disclose the preparation of hyperpolarized 13C dialkyi succinate compounds and hyperpolarized 13C dialkyi fumarate compounds and their use in real time, in vivo metabolic imaging of the TCA cycle. In another embodiment, a composition is provided, the composition comprising hyperpolarized diethyl 1- 13 C succinate and diethyl 1,4- 13 C succinate.
摘要:
Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
摘要:
This invention relates to a formulation comprising a compound of formula (I) where R1 and R2 are each independently hydrogen, optionally substituted C1-18 alkyl, optionally substituted C1-18 alkenyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl or optionally substituted aryl; provided that the total number of carbon atoms in R1 and R2 is an integer from 5 to 40 inclusive; the use of a compound of formula (I) (i) as an adjuvant provided that the total number of carbon atoms in R1 and R2 is an integer from 5 to 40 inclusive; and (ii) as a solvent provided that the total number of carbon atoms in R1 and R2 is an integer from 5 to 20 inclusive; to certain novel compounds of formula (I) and to a process for preparing those novel compounds.
摘要:
Compounds useful as plasticizers and the synthesis thereof are disclosed. In general, the invention includes mixed alkyl/aryl diesters where the aryl and alkyl ester moieties are attached to a cyclic structure at vicinal carbons. The invention also includes synthetic processes of making such compounds.
摘要:
The subject matter of the invention is the use of metal salts of trifluoromethane sulphonic acid as esterification catalyst and/or transesterification catalyst for the production of hydroxycarboxylic acid esters.
摘要:
Structural, radically curable resin compositions suitable for (re)lining contain: a. 30-70 wt. % of a resin characterized by (i) a molecular weight Mn between 500 and 3000 and (ii) an acid value between 0 and 30 mg KOH/g resin, and wherein at least 80% of the total amount of resin is vinyl ester resin, b. 30-70 wt. % of at least one reactive diluent, characterized in that at least 25% of the reactive diluent is a difunctional diluent having a molecular weight Mn between 200 and 500 and the optional monofunctional diluent having a molecular weight Mn between 100 and 200, c. 0.00001-5 wt. % initiator, d. 0.00001-5 wt. % inhibitor. wherein the average molecular weight per reactive unsaturation (WPU) of the components (a) and (b) is equal or greater than 190 Dalton and that the amount of styrene in the resin composition is less than 5 wt. % (calculated as wt. % of the total weight of the components (a), (b), (c) and (d)).
摘要:
Compositions comprising 1,3-propanediol and an extraction product are provided, and the 1,3-propanediol in the composition is biologically derived. Also provided are processes for extracting an extract from a source. These processes comprise providing 1,3-propanediol and mixing the 1,3-propanediol with the source. This serves to extract the extract from the source into the 1,3-propanediol. The processes also include separating the source from the ester and extract.
摘要:
Compositions comprising 1,3-propanediol and an extraction product are provided, and the 1,3-propanediol in the composition is biologically derived. Also provided are processes for extracting an extract from a source. These processes comprise providing 1,3-propanediol and mixing the 1,3-propanediol with the source. This serves to extract the extract from the source into the 1,3-propanediol. The processes also include separating the source from the ester and extract.
摘要:
Malodour counteracting preparations for oral use comprising esterified fumarates of the formula (I) wherein X and Y have the same meaning as given in the description, is disclosed. Furthermore, the invention refers to a process for their preparation and to their use for preventing or reducing oral malodour.